CPT 4171F ESA Therapy Reimbursement & Policy

CPT code 4171F documents a provider’s prescription of erythropoiesis-stimulating agent (ESA) therapy for anemia associated with chronic kidney disease (CKD). Nationally, this code matters because ESA prescribing affects clinical outcomes for CKD patients, links to quality measures around anemia management, and intersects with payer coverage policies for biologic and specialty medications. Proper coding ensures accurate capture of treatment intent and supports care coordination for patients receiving ESA therapy.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ESA use in CKD-related anemia, how CPT code 4171F is used in documentation, and the types of benchmarks and policy elements typically relevant for this service (coverage criteria, prior authorization triggers, and quality measure alignment). The publication also summarizes expected sites of service and service type to aid billing and clinical staff.

This resource is written for a national audience and is intended to clarify the clinical meaning and administrative purpose of CPT code 4171F. Data not available in the input will be noted where necessary in detailed sections.

Billing Code Overview

CPT code 4171F indicates that the provider prescribes erythropoiesis stimulating agent therapy to treat anemia in a patient with chronic kidney disease (CKD). This billing code documents clinical management focused on initiating or continuing therapy with erythropoiesis-stimulating agents for patients whose anemia is related to CKD.

Service type: Medication management / Pharmacologic therapy (erythropoiesis-stimulating agents)

Typical site of service: Outpatient clinic, nephrology practice, or dialysis center

Data not available in the input.

Clinical Context

A typical patient is a 62-year-old with stage 4 chronic kidney disease and symptomatic anemia (fatigue, dyspnea on exertion) whose hemoglobin has fallen below the clinic’s treatment threshold despite iron repletion. The nephrology or primary care provider evaluates labs, documents baseline hemoglobin, ferritin, transferrin saturation, and assesses bleeding risk and comorbidities. After shared decision-making and if contraindications are absent, the provider prescribes an erythropoiesis-stimulating agent (ESA) such as epoetin alfa or darbepoetin alfa to treat anemia related to chronic kidney disease. The workflow includes documentation of indication (CKD with corresponding diagnosis code), laboratory values supporting the anemia diagnosis, prior iron therapy status, the selected ESA agent and dosing plan, monitoring schedule for hemoglobin and blood pressure, and safety counseling about potential risks (thromboembolism, hypertension). Prescriptions may be written for outpatient administration at a dialysis unit, clinic, or home health nursing service, with follow-up visits or lab checks scheduled within 2–4 weeks after initiation and periodically thereafter to guide dose adjustments.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service	Use when an E/M visit for anemia management is distinct from ESA prescription/administration documentation on the same day

Taxonomy Code	Specialty	Notes
`2080P0207X`	Nephrology	Nephrologists commonly manage anemia of CKD and prescribe ESAs
`207Q00000X`	Internal Medicine	Internists manage CKD-associated anemia in outpatient settings
`207L00000X`	Family Medicine	Family physicians prescribe and monitor ESAs for CKD patients
`207K00000X`	Medical Oncology	Oncologists may co-manage anemia when cancer coexists with CKD
`251S00000X`	Nurse Practitioner	NPs in nephrology or primary care frequently initiate and adjust ESA therapy

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`N18.4`	Chronic kidney disease, stage 4 (severe)	Advanced CKD causing decreased erythropoietin production and anemia; common indication for ESA therapy
`N18.5`	Chronic kidney disease, stage 5	End-stage CKD with severe anemia often treated with ESAs, especially in dialysis patients
`D63.1`	Anemia in chronic kidney disease	Direct diagnosis that indicates anemia attributable to CKD and supports ESA prescription
`D50.9`	Iron deficiency anemia, unspecified	Must be considered and treated prior to or concurrently with ESA therapy; influences management
`I10`	Essential (primary) hypertension	Common comorbidity; ESA therapy can raise blood pressure and requires monitoring
`D65`	Disseminated intravascular coagulation	Represents bleeding/thrombotic risk contexts where ESA risks must be weighed (less common)
`Z79.899`	Other long term (current) drug therapy	Used when documenting ongoing chronic therapies, including repeated ESA use

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)	Used when ESA is administered by injection in clinic or home health
`96361`	Intravenous infusion for therapy, prophylaxis, or diagnosis; initial, up to 1 hour (may be used for IV ESA administration depending on product)	Used when ESA is administered as an IV infusion requiring timed reporting
`99406`	Smoking and tobacco use cessation counseling, intermediate, 3–10 minutes	Example of an unrelated E/M counseling service that may be provided during the visit and reported separately when applicable
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common level of E/M used to evaluate CKD anemia, review labs, and prescribe ESA
`36415`	Collection of venous blood by venipuncture	Performed to obtain hemoglobin, ferritin, and iron studies used to guide ESA therapy
`99497`	Advance care planning including preparation and discussion of advance directives, first 30 minutes	Occasionally documented during complex CKD care visits; report when performed and documented

OpenPayer

Summary & Overview

CPT 4171F: Erythropoiesis-Stimulating Agent Therapy for CKD-Related Anemia